Equities Analysts Issue Forecasts for AQST FY2026 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Analysts at HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a report issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.56) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

A number of other research analysts have also recently weighed in on AQST. Lake Street Capital dropped their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Friday. Finally, Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $10.57.

Aquestive Therapeutics Trading Up 3.9 %

NASDAQ:AQST opened at $2.64 on Tuesday. The company has a market capitalization of $261.02 million, a P/E ratio of -5.87 and a beta of 2.76. The firm has a 50-day moving average price of $3.05 and a two-hundred day moving average price of $4.07. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analyst estimates of $13.11 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after purchasing an additional 82,958 shares during the last quarter. Geode Capital Management LLC grew its holdings in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after buying an additional 90,543 shares during the period. State Street Corp increased its stake in shares of Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after acquiring an additional 512,682 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Aquestive Therapeutics by 6.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock valued at $3,505,000 after acquiring an additional 61,200 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.